Aeterna Zentaris Inc. (Nasdaq: AEZS) Shares Up on Expectations of 2017 Developments

Aeterna Zentaris Inc. – Nasdaq: AEZS

Aeterna Zentaris shares traded up over 20% today on the belief that the company will be completed with Phase 3 testing and begin commercialization of two products in 2017. AEZS, traded on the Nasdaq, experienced volumes ten times normal in today’s trading session and the shares settled at $3.15.

Canadian-based Aeterna Zentaris has two drugs far along in its pipeline. The first is Macrilen, a drug designed to evaluate adults for growth hormone deficiency, is expected to deliver top-line results once the final stages of pivotal clinical testing are completed in early-2017. The other drug in development is Zoptrex, a treatment for advanced endometrial cancer, which has been re-engineered from an established chemotherapeutic agent. The new treatment is rumored to be safer in terms of side-effects, and reportedly provides extended chances for survival for women with advanced endometrial cancer.

AEZS shares have experienced negative EPS for the last five years but year-on-year EPS losses have been narrowing. In 2011 AEZS lost $168.75 per share. That loss narrowed to $18.18 in 2015. AEZS sales have been inconsistent and in 2015 Aeterna Zenatris posted just $500k. Two firms follow Aeterna Zentaris and both rate AEZS shares as a “Strong Buy” with a price target of $8.75.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol AEZS
Last Price a/o 6:09 PM EST  $                      3.20
Average Volume                    279,030
Market Cap (mlns)  $                    37.55
Sales (mlns) $0.70
Shares Outstanding (mlns) 11.92
Share Float (mlns) 11.61
Shortable Yes
Optionable Yes
Inside Ownership 0.60%
Short Float 6.55%
Short Interest Ratio 2.73
Quarterly Return -17.54%
YTD Return -12.50%
Year Return 0.64%